Organon & Co.

OGNintermediary

Organon is a women's health-focused pharmaceutical company spun off from Merck in 2021, combining contraceptive and fertility products with a growing biosimilars portfolio.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($6.3B)

静态数据（加载实时财务…）

Women's Health (28%)

Biosimilars (18%)

Established Brands (54%)

业务板块构成与主要客户

产品详情

Nexplanon25%

Long-acting reversible contraceptive implant — #1 in its class

Fertility (Follistim, Ganirelix)15%

Hormone therapies for assisted reproduction

Biosimilars20%

Renflexis, Hadlima, and other biosimilar products

Established Brands40%

Legacy Merck products including Zetia, Nasonex, Cozaar

供应链关系

合作伙伴

Merck & Co.

Spun off from Merck in 2021

影响: Medium — legacy Merck product rights

竞争对手

Viatris Inc.

Biosimilar market

影响: Medium — competing biosimilar portfolios

主要客户

Walgreens Boots Alliance

Pharmacy retail distribution

影响: Low — indirect distribution

宏观与市场背景

제약 / 바이오行业新闻

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化剂

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

点击「获取 AI 分析」以获得 Organon & Co. 的 AI 供应链分析。

企业信息

总部

Jersey City, New Jersey, USA

成立时间

2021

员工人数

10,000+

官网

organon.com

行业概况 — 제약 / 바이오

行业新闻